Home › Wilms Tumor
Pag-aaral pangklinika para sa Wilms Tumor na nagre-recruit sa U.S.
17 pag-aaral para sa Wilms Tumor ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Washington, DC7 pag-aaral
- Memphis, TN6 pag-aaral
- Atlanta, GA5 pag-aaral
- Minneapolis, MN4 pag-aaral
- Houston, TX4 pag-aaral
- Greenburgh, NY4 pag-aaral
- Los Angeles, CA4 pag-aaral
- New York City, NY4 pag-aaral
- Philadelphia, PA4 pag-aaral
- Boston, MA4 pag-aaral
- Mountain View, CA4 pag-aaral
- Aurora, CO4 pag-aaral
- Cincinnati, OH4 pag-aaral
- Chicago, IL4 pag-aaral
- St. Louis, MO4 pag-aaral
- Ann Arbor, MI3 pag-aaral
- Birmingham, AL3 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- California5 pag-aaral
- Colorado4 pag-aaral
- District of Columbia7 pag-aaral
- Florida3 pag-aaral
- Georgia5 pag-aaral
- Illinois4 pag-aaral
- Massachusetts4 pag-aaral
- Michigan3 pag-aaral
- Minnesota5 pag-aaral
- Missouri4 pag-aaral
- New York6 pag-aaral
- Ohio5 pag-aaral
- Pennsylvania4 pag-aaral
- Tennessee6 pag-aaral
- Texas6 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04616560Biomarkers of Resiliency In Childhood Cancer Surgery
Nagre-recruitObservasyonal na pag-aaral
Edad 3 hanggang 25 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06674811A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Nagre-recruitPhase 2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04322318Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Nagre-recruitPhase 1
Edad 1 hanggang 23 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT04715191Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06625190Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update May 19, 2026 · NCT04901702B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update May 19, 2026 · NCT04897321A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Nagre-recruitPhase 2
12 Months · Lahat ng kasarian · Na-update May 6, 2026 · NCT05985161Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT04968990Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04308330Pencil Beam Scanning in Patients With Renal Tumors
Nagre-recruitMaagang Phase 1
Edad 0 hanggang 30 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT03810651Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Nagre-recruitPhase 1
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Nagre-recruitPhase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Nob 3, 2025 · NCT06198296A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nagre-recruitPhase 2
18 Months – 40 Years · Lahat ng kasarian · Na-update Ago 12, 2025 · NCT05135975International PPB/DICER1 Registry
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
0 Minutes – 100 Years · Lahat ng kasarian · Na-update Ene 30, 2025 · NCT03382158Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.